A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms LONGTERMS
- Sponsors Novartis; Novartis Pharmaceuticals
- 29 Mar 2018 This trial has been competed in Portugal.
- 28 Mar 2018 This trial has been competed in Slovakia.
- 27 Mar 2018 Planned End Date changed from 29 Sep 2018 to 28 Sep 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History